Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2019 Nov 18;14(22):3962-3968.
doi: 10.1002/asia.201900841. Epub 2019 Aug 7.

New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

Erik De Clercq  1
Affiliations
Review

New Nucleoside Analogues for the Treatment of Hemorrhagic Fever Virus Infections

Erik De Clercq. Chem Asian J. .

Abstract

Eight different compounds, all nucleoside analogues, could presently be considered as potential drug candidates for the treatment of Ebola virus (EBOV) and/or other hemorrhagic fever virus (HFV) infections. They can be considered as either (i) adenine analogues (3-deazaneplanocin A, galidesivir, GS-6620 and remdesivir) or (ii) guanine analogues containing the carboxamide entity (ribavirin, EICAR, pyrazofurin and favipiravir). All eight owe their mechanism of action to hydrogen bonded base pairing with either (i) uracil or (ii) cytosine. Four out of the eight compounds (galidesivir, GS-6620, remdesivir and pyrazofurin) are C-nucleosides, and two of them (GS-6620, remdesivir) also contain a phosphoramidate part. The C-nucleoside and phosphoramidate (and for the adenine analogues the 1'-cyano group as well) may be considered as essential attributes for their antiviral activity.

Keywords: antivirals; ebola; hemorrhagic fever viruses; nucleoside analogues.

PubMed Disclaimer

Conflict of interest statement

The author declares no conflict of interest.

Figures

Figure 1
Figure 1
Chemical structures.
Scheme 1
Scheme 1
Metabolism of T‐705.
Figure 2
Figure 2
Hydrogen bonding.
Scheme 2
Scheme 2
(Candidate) antiviral compounds against EBOV.
See this image and copyright information in PMC

References

    1. Andrei G., De Clercq E., Antiviral Res. 1993, 22, 45–75. - PubMed
    1. McCormick J. B., King I. J., Webb P. A., Scribner C. L., Craven R. B., Johnson K. M., Elliott L. H., Belmont-Williams R., N. Engl. J. Med. 1986, 314, 20–26. - PubMed
    1. Sidwell R. W., Huffman J. H., Khare G. P., Allen L. B., Witkowski J. T., Robins R. K., Science 1972, 177, 705–706. - PubMed
    1. De Clercq E., Med. Res. Rev. 2009, 29, 611–645. - PubMed
    1. Matsuda A., Minakawa N., Sasaki T., Ueda T., Chem. Pharm. Bull. 1988, 36, 2730–2733. - PubMed

MeSH terms